Allakos Announces Pricing of Public Offering of Common Stock
October 28, 2020 20:20 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related...
Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020
October 27, 2020 19:56 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and mast...
Allakos Announces Proposed Public Offering of Common Stock
October 27, 2020 16:09 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related...
Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)
October 26, 2020 07:00 ET
|
Allakos Inc.
-- Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustained eosinophil suppression supporting once monthly dosing -- -- Management to host conference call and...
Results from Prospective Prevalence Study Indicate that Eosinophilic Gastritis and Eosinophilic Duodenitis May be Significantly Underdiagnosed
October 26, 2020 07:00 ET
|
Allakos Inc.
-- 45% (181/405) of symptomatic patients biopsied with chronic functional gastrointestinal symptoms met the histologic criteria for eosinophilic gastritis and/or eosinophilic duodenitis -- --...
Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine
October 21, 2020 17:00 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related...
Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update
August 10, 2020 08:00 ET
|
Allakos Inc.
REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-related...
Allakos Initiates Patient Recruitment for AK002 Registrational Studies
June 03, 2020 08:01 ET
|
Allakos Inc.
-- Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis -- -- Top-line safety and efficacy results from both studies expected in...
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the Digital EAACI Annual Congress 2020
May 21, 2020 08:01 ET
|
Allakos Inc.
REDWOOD CITY, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell...
Allakos Announces a Presentation of Antolimab in Patients with Severe Allergic Conjunctivitis at the 2020 ASCRS Virtual Annual Meeting
May 11, 2020 08:01 ET
|
Allakos Inc.
REDWOOD CITY, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell...